James Investment Research’s AbbVie ABBV Stock Holding History

James Investment Research’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$8.59M	Sell	34,143 -410	-1%	-$88.2K	0.87%	28
2026 Q1	$7.51M	Sell	34,553 -101	-0.3%	-$22.4K	0.84%	31
2025 Q4	$7.92M	Sell	34,654 -239	-0.7%	-$54.4K	0.86%	28
2025 Q3	$8.08M	Buy	34,893 +52	+0.1%	+$10.6K	0.88%	29
2025 Q2	$6.47M	Sell	34,841 -570	-2%	-$106K	0.77%	34
2025 Q1	$7.42M	Sell	35,411 -2,099	-6%	-$408K	0.94%	30
2024 Q4	$6.67M	Sell	37,510 -583	-2%	-$107K	0.79%	35
2024 Q3	$7.52M	Sell	38,093 -892	-2%	-$166K	0.87%	32
2024 Q2	$6.69M	Sell	38,985 -205	-0.5%	-$34K	0.8%	36
2024 Q1	$7.14M	Sell	39,190 -1,454	-4%	-$251K	0.85%	37
2023 Q4	$6.3M	Sell	40,644 -1,555	-4%	-$227K	0.79%	40
2023 Q3	$6.29M	Sell	42,199 -543	-1%	-$79.7K	0.83%	37
2023 Q2	$5.76M	Sell	42,742 -427	-1%	-$62.6K	0.74%	42
2023 Q1	$6.88M	Buy	43,169 +2,043	+5%	+$312K	0.91%	34
2022 Q4	$6.65M	Buy	41,126 +2,248	+6%	+$345K	0.93%	31
2022 Q3	$5.22M	Buy	38,878 +15,019	+63%	+$2.16M	0.74%	41
2022 Q2	$3.65M	Buy	23,859 +175	+0.7%	+$26.7K	0.49%	65
2022 Q1	$3.84M	Sell	23,684 -2,213	-9%	-$321K	0.4%	76
2021 Q4	$3.51M	Buy	25,897 +122	+0.5%	+$14.4K	0.32%	84
2021 Q3	$2.78M	Buy	25,775 +535	+2%	+$61.1K	0.26%	97
2021 Q2	$2.84M	Buy	25,240 +2,430	+11%	+$274K	0.24%	109
2021 Q1	$2.47M	Buy	22,810 +22,472	+6,649%	+$2.4M	0.22%	115
2020 Q4	$36K	Sell	338 -31	-8%	-$2.98K	﹤0.01%	408
2020 Q3	$32K	Buy	+369	New	+$34.7K	﹤0.01%	374
2019 Q2	–	Sell	-142	Closed	-$11K	–	665
2019 Q1	$11K	Sell	142 -12,377	-99%	-$1.01M	﹤0.01%	726
2018 Q4	$1.15M	Buy	+12,519	New	+$1.1M	0.07%	251
2018 Q3	–	Sell	-19,605	Closed	-$1.82M	–	782
2018 Q2	$1.82M	Buy	19,605 +2,505	+15%	+$245K	0.07%	418
2018 Q1	$1.62M	Sell	17,100 -900	-5%	-$98.9K	0.06%	417
2017 Q4	$1.74M	Buy	+18,000	New	+$1.7M	0.06%	377
2016 Q4	–	Sell	-95	Closed	-$6K	–	547
2016 Q3	$6K	Hold	95	–	–	﹤0.01%	501
2016 Q2	$6K	Sell	95 -105	-53%	-$6.4K	﹤0.01%	453
2016 Q1	$11K	Hold	200	–	–	﹤0.01%	422
2015 Q4	$12K	Sell	200 -400	-67%	-$23K	﹤0.01%	447
2015 Q3	$33K	Hold	600	–	–	﹤0.01%	365
2015 Q2	$40K	Hold	600	–	–	﹤0.01%	375
2015 Q1	$35K	Hold	600	–	–	﹤0.01%	401
2014 Q4	$39K	Hold	600	–	–	﹤0.01%	396
2014 Q3	$35K	Sell	600 -100	-14%	-$5.55K	﹤0.01%	406
2014 Q2	$39K	Hold	700	–	–	﹤0.01%	389
2014 Q1	$36K	Buy	700 +100	+17%	+$5.05K	﹤0.01%	394
2013 Q4	$32K	Hold	600	–	–	﹤0.01%	397
2013 Q3	$27K	Sell	600 -505	-46%	-$22.4K	﹤0.01%	403
2013 Q2	$45K	Buy	+1,105	New	+$48.3K	﹤0.01%	371

Other funds holding ABBV

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

James Investment Research's ABBV Position: Q2 2026 in Review

James Investment Research reduced its AbbVie (ABBV) stake by 1.2% in Q2 2026, selling an estimated $88.2K and leaving 34,143 shares worth $8.59M. The position accounts for 0.87% of the portfolio, ranked #28.

James Investment Research first reported a position in ABBV in Q2 2013 and has held it in 43 quarters since. 4,208 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

James Investment Research held 34,143 shares of AbbVie worth $8.59M as of Q2 2026.
James Investment Research sold 410 AbbVie shares in Q2 2026, an estimated $88.2K.
AbbVie made up 0.87% of James Investment Research's portfolio in Q2 2026, its #28 holding.
James Investment Research first reported a position in AbbVie in Q2 2013 and has held it in 43 quarters since.
4,208 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on James Investment Research's 13F filing for Q2 2026, filed 24 Jul 2026.